Zacks Investment Research·3d ago
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
Denali Therapeutics is a pre-commercial biotech focused on CNS diseases, with its value hinging on pipeline execution. The company's financials reveal a sustained and accelerating cash burn, with quarterly operating losses exceeding $130M and free cash flow deteriorating to -$231.5M in 2026Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $0.37+236.6% vs -$0.27 | $18M+40.3% vs $13M |
Q3 2026 Aug 6, 2026 | -$0.68-32.5% vs -$0.51 | $4M+67.3% vs $2M |
Q2 2026 May 7, 2026 | -$0.69+5.5% vs -$0.73 | — vs $3M |
Q1 2026 Feb 26, 2026 | -$0.73+2.7% vs -$0.75 | — vs $3M |
Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
Denali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of clinical-trial participants to commercial therapy supported a faster-than-expected launch.
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.
Benchmark DNLI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Denali Therapeutics Inc. (DNLI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.07 | $3.19B | -12.26 | — | -1470.5% | -33.98% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $6.41 | $413.58M | -44.12 | -0.3% | -3.45% | -2% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $132.04 | $8.49B | 27.67 | -89.41% | 62.04% | 42.83% | — |
Denali Therapeutics Inc. (DNLI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Denali Therapeutics Inc. (DNLI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 28, 2026·SEC
Jun 18, 2026·SEC
Get notified when DNLI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Denali Therapeutics Inc. (DNLI) stock FAQ — growth, dividends, profitability & financials explained
Denali Therapeutics Inc. (DNLI) reported $21.4M in revenue over the trailing twelve months.
No. Denali Therapeutics Inc. (DNLI) reported a net loss of $314.4M over the trailing twelve months.
Denali Therapeutics Inc. (DNLI) had a return on equity (ROE) of -34.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Denali Therapeutics Inc. (DNLI) had negative free cash flow of $450.0M over the trailing twelve months.
